Skip to main content

ANTX

Stock
Healthcare
Biotechnology

Performance overview

ANTX Price
Price Chart

Forward-looking statistics

Beta
0.48
Risk
90.69%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

A clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases.

Company info

SectorHealthcare
IndustryBiotechnology
Employees32
Market cap$43.0M

Fundamentals

Enterprise value-$35.1M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.51
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$366K
Avg trading volume (10 day)$133K
Put-call ratio—

Macro factor sensitivity

Growth-29.8
Credit+32.6
Liquidity+29.6
Inflation-31.3
Commodities-30.0
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio-0.91
Price to sales—
P/E Ratio-0.91
Enterprise Value to Revenue—
Price to book0.43

Upcoming events

Next earnings dayMay 15, 2024
Next dividend day—
Ex. dividend day—

News

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

Zacks Investment Research (August 19, 2024)
RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15

AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million.  The Company announced IPO plans earlier this month.

Benzinga (March 25, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free